Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Would love to hear your thoughts #Pharma #PharmaIndustry #Healthcare #GLP1 #Semaglutide #DiabetesCare #ObesityCare #IndianPharma #PharmaStrategy #HealthcareInnovation #ChronicCare #MarketTrends #BusinessStrategy #PharmaMarketing #FutureOfHealthcare To view or add a comment, sign in The last week in Indian Pharma was all about semaglutide
Stir 30 seconds
The trouble is you cannot be assured of that because you don't really know what's going on behind the door at the pharmacy
doi:10.1056/NEJMoa1901118 17
Discontinuation due to adverse events was 3.8% (4 mg), 11.6% (9 mg) and 7.7% (12 mg), versus 4.9% on placebo
Also, we know that these drugs do not cross the blood brain barrier
US$ 20.28
US$ 29.40
US$ 23.19
